RxDoctor Payments Data

Edgar Jay Evangelista, MD

Clinical Neurophysiology · Las Vegas, NVNPI 1669693081

Payments from drug & device makers

$19,540in general payments, 2019–2025

Across 946 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • EMD Serono, Inc.$2K
  • UCB, Inc.$1K
  • Amgen$1K
  • Novartis$1K
  • Biogen$1K
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$4742%
  • Food & beverage$18,65196%
  • Education$2041%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)146$2,530
EMD Serono, Inc.92$1,929
UCB, Inc.57$1,258
Amgen(2 entities)43$1,174
Novartis66$1,075
Biogen60$1,017
Bristol Myers Squibb23$655
SK Life Science, Inc.22$568
Eisai Inc.43$552
Lundbeck LLC21$523
Pfizer29$497
Mallinckrodt Hospital Products Inc.19$479
Argenx US, Inc.21$465
Avanir Pharmaceuticals, Inc.25$438
Teva Pharmaceuticals USA, Inc.18$423
Genentech USA, Inc.17$355
Lilly USA, LLC20$328
Sanofi14$325
Acadia Pharmaceuticals Inc17$317
Livanova USA, Inc.10$264
Harmony Biosciences LLC8$260
Johnson & Johnson(2 entities)10$258
Upsher-smith Laboratories LLC12$229
Galderma Laboratories, L.p.1$211
AstraZeneca9$205
Medtronic(2 entities)4$188
Sunovion Pharmaceuticals Inc.12$184
E.r. Squibb & Sons, L.L.C.2$160
Neurelis, Inc.6$158
Acorda Therapeutics, Inc9$156
Nevro Corp.2$156
Mallinckrodt Enterprises LLC6$149
Vanda Pharmaceuticals Inc.6$142
Grifols USA, LLC6$139
MDD US Operations, LLC7$139
Biohaven Pharmaceutical Holding Company Ltd.10$136
Axsome Therapeutics, Inc.6$134
Avion Pharmaceuticals4$113
Alnylam Pharmaceuticals Inc.4$108
TG Therapeutics, Inc.4$97
Biohaven Pharmaceuticals, Inc.6$94
Assertio Therapeutics, Inc.6$92
Takeda Pharmaceuticals U.S.A., Inc.3$90
Arbor Pharmaceuticals, Inc.5$67
Catalyst Pharmaceuticals, Inc.2$62
Impel Pharmaceuticals Inc.3$61
Banner Life Sciences, LLC3$54
Scilex Pharmaceuticals Inc.3$53
CSL Behring3$51
Vertical Pharmaceuticals, LLC3$50
Sanofi-aventis U.S. LLC2$46
Kyowa Kirin, Inc.2$42
Merz Pharmaceuticals, LLC1$39
Amneal Pharmaceuticals LLC2$39
Neurocrine Biosciences, Inc.2$36
C2n Diagnostics, LLC1$26
Tanabe Pharma America, Inc.1$21
GE HealthCare1$21
Adamas Pharmaceuticals, Inc.1$21
Avadel CNS Pharmaceuticals, LLC1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$124,079
Medicare patients
175
Services billed
4,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5048$1,471,384
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$292,918
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$287,853
OctagamImmun Globg(Igg)/Malt/Iga Ov5013$268,002
VyvgartEfgartigimod Alfa-Fcab12$222,854
Nurtec OdtRimegepant Sulfate25$43,824
Pyridostigmine Bromide ErPyridostigmine Bromide23$31,104
Emgality PenGalcanezumab-Gnlm27$21,310
Aimovig AutoinjectorErenumab-Aooe16$14,481
Levetiracetam45$2,451
Eletriptan HbrEletriptan Hydrobromide19$1,617
Pyridostigmine Bromide24$1,372
Carbidopa-LevodopaCarbidopa/Levodopa44$1,287
Divalproex Sodium23$1,281
Primidone33$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$51$1,471,38448 claims
PfizerOctagam, Nurtec Odt$497$311,82638 claims
Grifols USA, LLCGamunex-C$139$292,91813 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$90$287,85312 claims
Argenx US, Inc.Vyvgart$465$222,85412 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$39$1,37224 claims
Upsher-smith Laboratories LLCTopiramate$229$22628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Las Vegas

Where these figures come from

Is this you, or does something look wrong? →